| CYT387 |
| N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide |
| (CAS 1056634-68-4) |
 |
| Description： |
CYT387 is an inhibitor of Janus kinases JAK1 and JAK2, acting as an ATP competitor with IC50 values of 11 and 18 nM, respectively. The inhibitor is significantly less active towards other kinases, including JAK3 (IC50 = 0.16 μM).[1]
As of 2011, CYT387 is being developed as a drug for myelofibrosis and currently undergoes Phase I/II clinical trials. Additional potential treatment indications for CYT387 include other myeloproliferative neoplasms, cancer (solid and liquid tumors) and inflammatory conditions.[2]
The drug was originally discovered by Australian drug discovery company Cytopia, then developed by YM BioSciences Inc. (since acquired by Gilead Sciences as of 2013) |
| Product No. |
KT00324 |
| Product Name |
CYT387 |
| Synonyms |
Momelotinib |
| Formal Name |
N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide |
| CAS Number |
1056634-68-4 |
| Molecular Formula |
C23H22N6O2 |
| Formula Weight |
414.5 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
(3R,4S)-Tofacitinib
(3S,4R)-Tofacitinib
(3S,4S)-Tofacitinib
AG-490
AT9283
AZD-1480
BMS-911543
CEP-33779
GLPG0634
JANEX-1 |
|
